To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:255 Issue:3 Number:27 ISSN#:2564-2537
RCT
ACE Report #14645
Ace Report Cover Tumour

Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma


How to Cite

OrthoEvidence. Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma. ACE Report. 2022;255(3):27. Available from: https://myorthoevidence.com/AceReport/Report/14645

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial

Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332

Contributing Authors:
Z Li C Li P Li Y Li J Lai S Rastogi

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

200 pediatric osteosarcoma patients were randomized to receive a single intravenous dose of palonosetron or granisetron for antiemetic prophylaxis. The primary outcome was patient response to treatment in the first 24 hours after chemotherapy (complete response; partial response; failure). Adverse events were also recorded. Results found that patients who received palonosetron had a significantly ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.